arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Nuvectis Pharma, Inc.

NVCT

$21.14 ▼ -1.88 (-8.17%) at close

6 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Nuvectis Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $461.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -118.3% ↗

FCF / Share $-0.73 ↘

Trailing P/E —

Price / Book 29.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-26.44M

↓ -39.2% —

FCF / Share Free cash flow per share

$-0.73

↓ -2.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2020

FY 2021

$0.00

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	-18.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	22.4% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	5.3% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	50.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-39.2% Weak ↓ Weak Declining Year-over-year change in net income	14.6% Fair ↑ Fair Improving Year-over-year change in net income	-16.6% Weak Weak Year-over-year change in net income	-48.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-2.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	30.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	4.3% Caution Caution Year-over-year change in free cash flow	51.9% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	0.61x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-118.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-161.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-148.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-106.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	92.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-87.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-106.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-119.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-94.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-193.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-143.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1057%)	-195.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1404%)	-182.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1316%)	-134.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-995%)	117.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+681%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-31.63M	$-18.53M	$-19.13M	$-19.99M	$-5.74M	—

📊 What does each share earn? 7 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-1.32	$-1.11	$-1.43	$-1.51	$-3.02	—
Free Cash Flow per Share (USD)	$-0.73	$-0.72	$-1.03	$-1.07	$-2.23	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	$0.00	—	—
Book Value per Share (USD)	$0.72	$0.50	$0.70	$0.97	$-2.44	—
Tangible Book Value per Share (USD)	$0.72	$0.50	$0.70	$0.97	$-2.44	—
Basic Weighted Avg Shares (shares)	21.81M	17.11M	15.56M	12.66M	4.27M	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$18.41M	$9.71M	$12.20M	$14.22M	$3.41M	—
Total Equity (USD)	$18.41M	$9.71M	$12.20M	$14.22M	$-11.01M	$-10.00K

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Net Income, GAAP (USD)	$-26.44M	$-19.00M	$-22.26M	$-19.09M	$-12.89M	—
Operating Cash Flow (USD)	$-16.01M	$-12.25M	$-15.95M	$-13.56M	$-9.50M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters

Nuvectis Pharma, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NVCT with peers